Adlai Nortye Secures $230 Million Deal to Accelerate Cancer Drug Development in China

North Brunswick, Monday, 29 December 2025.
Adlai Nortye partners with ASK Pharm in a deal valued at $230 million to develop the AN9025 cancer therapy in Greater China, aiming for clinical trials in early 2026.